Sugi Predict
/ Targets
/ CLN6
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to CLN6 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis |
PHASE4 | COMPLETED |
| Gene Therapy Trial for CLN6 Batten Disease |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Gene Therapy For Children With Variant Late Infantile Neuronal Ceroid Lipofuscinosis 6 (vLINCL6) Disease |
PHASE1/PHASE2 | COMPLETED |
| A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease |
PHASE1/PHASE2 | COMPLETED |
| Gene Therapy Study for Children With CLN5 Batten Disease |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis |
PHASE2 | COMPLETED |
| Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2 |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| AAVRh.10 Administered to Children With Late Infantile Neuronal Ceroid Lipofuscinosis |
PHASE1/PHASE2 | COMPLETED |
| An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease |
PHASE1/PHASE2 | COMPLETED |
| A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease |
PHASE1/PHASE2 | RECRUITING |
| Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) |
PHASE1 | COMPLETED |
| Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis |
PHASE1 | COMPLETED |
| Safety and Efficacy Study of HuCNS-SC in Subjects With Neuronal Ceroid Lipofuscinosis |
PHASE1 | WITHDRAWN |
| Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene Transfer |
nan | ACTIVE_NOT_RECRUITING |
| Natural History of Neuronal Ceroid Lipofuscinosis, Batten's CLN6 Diseae |
nan | ACTIVE_NOT_RECRUITING |
| Investigations of Juvenile Neuronal Ceroid Lipofuscinosis |
nan | RECRUITING |
| Trehalose in Subjects With Neuronal Ceroid Lipofuscinoses |
nan | COMPLETED |
| Examining Developmental Outcomes of Children Diagnosed With CLN2 Disease |
nan | ENROLLING_BY_INVITATION |
| Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities |
nan | COMPLETED |
| A Natural History Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5) |
nan | COMPLETED |
| A Multicenter Selective Screening Study to Investigate the Frequency of Neuronal Ceroid Lipofuxinosis Type 2 (CLN2) |
nan | RECRUITING |
| Cerliponase Alfa Observational Study in the US |
nan | ACTIVE_NOT_RECRUITING |
| Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database |
nan | RECRUITING |
| Italian NCL Registry: a Registry for NCL as an Integration Tool for Future Therapeutic Strategies |
nan | RECRUITING |
| An Observational Study in Children With CLN2 Batten Disease |
nan | WITHDRAWN |
| Genotype - Phenotype Correlations of LINCL |
nan | COMPLETED |
| A Retrospective, Natural History Study in Children With CLN2 |
nan | WITHDRAWN |
| Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients |
nan | ACTIVE_NOT_RECRUITING |
| The Classification and Cause of Leukodystrophies of Unknown Cause |
nan | COMPLETED |
| Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders |
nan | RECRUITING |
Related proteins — ESM-2 sequence neighbours (a CLN6 binder may also engage these)